CareNet, Inc.（TSE 2015）
In addition to providing physicians and medical professionals with helpful information for day-to-day clinical practice via the internet, CareNet, Inc. provides pharmaceutical companies with solutions for effectively carrying out activities for disseminating pharmaceuticals information.
SanBio Co., Ltd.（TSE 4592）
SanBio Co., Ltd. develops, manufactures, and sells regenerative cell drugs for treating central nervous system injuries or diseases such as stroke or traumatic brain injury. Currently the company is aiming to realize breakthrough therapeutic drugs for treating chronic- phase stroke and traumatic brain injury.
Modalis Therapeutics Corporation (Mothers 4883）
Possessing a powerful therapeutic drug creation platform based on the genome editing technology CRISPR, this bio-tech company aims to develop breakthrough therapeutic drugs for treating genetic diseases, which are said to number in excess of 6,000.
CellGenTech carries out practical development of adipocyte drugs for use in gene therapies incorporating therapeutic protein genes for the treatment of intractable diseases that occur due to congenital enzyme or functional protein deficiencies.
Gene Therapy Research Institution Co., Ltd.
With the aim of providing world-leading gene therapies for intractable diseases for which no effective treatments have existed until now, Gene Therapy Research Institution Co., Ltd. is consistently pursuing R&D from basic research through to clinical research, with particular focus on Parkinson’s disease, Amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease. Using their revolutionary approach of employing extraordinarily safe adeno-associated viruses (AAV) as viral vectors to deliver therapeutic genes, the company is developing internationally competitive innovative gene therapies.
DiscGenics is a startup specializing in regenerative therapies for IVD tissue, which functions to provide a cushion for the spine. Expectations are raised for the possibility that development of regenerative therapies for IVD tissue using allogeneic stem cells derived from the IVD nucleus pulposus may offer a high cost-effective treatment modality without requiring major surgical intervention. DiscGenics is currently developing regenerative therapies for the approval in the US and Japan.
ILC Therapeutics Ltd
ILC Therapeutics Ltd is a Scottish early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Cancer, Atopic Dermatitis, Psoriasis and Allergic Asthma amongst other conditions. More recently however, ILC Therapeutics has discovered that its hybrid, patented Interferon has potential to treat COVID-19. The company was founded by Prof. W. H. Stimson FRSE, who was the founder of the Department of Immunology at The University of Strathclyde.
Blueberry Therapeutics Limited
Blueberry Therapeutics is a clinical stage drug discovery and development company developing innovative topical nanomedicines in dermatology. The company focusses on hard to treat yet common disorders of the skin and nail with a vision to discover, develop and bring to market high value medicines in dermatology. The company develops low risk “Best in Class” novel nanoformulations of established drugs to enhance delivery through the skin and nail – enabling Blueberry to differentiate its products by matching or improve upon drug efficacy at significantly reduced doses. This also translates to improved patient safety and drug tolerability, increased compliance and reduced cost of goods.
Heartseed Inc. was founded in 2015 to develop and commercialize cardiac remuscularization therapy developed by Professor Keiichi Fukuda at the Department of Cardiology, Keio University, Tokyo, Japan. Their lead pipeline, HS-001, is allogeneic iPS cell-derived, highly purified ventricular cardiomyocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. In addition, Heartseed has proprietary technologies needed for disseminating cardiac therapy, such as purification, cell delivery and high-quality iPS cell production.